Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
Conditions
Interventions
rilzabrutinib
Locations
27
United States
The Oncology Institute of Hope & Innovation Site Number : 8400006
Cerritos, California, United States
TOI Clinical Research LLC_ Cerritos_Investigational Site Number: 8400006
Cerritos, California, United States
TOI Clinical Research LLC_Glendale_Investigational Site Number: 8400006
Glendale, California, United States
TOI Clinical Research LLC_Long Beach_Investigational Site Number: 8400006
Long Beach, California, United States
University of Southern California_Investigational Site Number: 8400009
Los Angeles, California, United States
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006
Santa Ana, California, United States
Start Date
December 7, 2021
Primary Completion Date
May 23, 2024
Completion Date
December 31, 2029
Last Updated
May 21, 2025
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions